Boston Scientific Agrees to Acquire Symetis
March 30, 2017—Boston Scientific Corporation announced a definitive agreement to acquire Symetis SA, a privately-held structural heart company based in Switzerland that is focused on transcatheter aortic valve replacement devices, for $435 million in cash. The acquisition is projected to close during the second quarter of 2017, subject to customary closing conditions.
According to Boston Scientific, the Symetis portfolio includes the Acurate TA and Acurate neo/TF valve systems for use in the treatment of high-risk patients with severe and symptomatic aortic valve stenosis. The devices are commercially available in Europe and in other geographies outside of the United States. They are not approved for use or sale in the United States.
Symetis is also developing the next-generation Acurate neo/AS valve system, which is currently in a clinical trial intended to serve as the basis for a future application for European CE Mark approval. The Acurate neo/AS valve system is not available for use or sale.
Boston Scientific noted that this agreement to acquire Symetis follows the company's recent acquisition of certain manufacturing assets of Neovasc, Inc., and demonstrates its continued investment in the structural heart business.